CA2652980A1 - Formulations d'oxymorphone robustes a liberation prolongee - Google Patents

Formulations d'oxymorphone robustes a liberation prolongee Download PDF

Info

Publication number
CA2652980A1
CA2652980A1 CA002652980A CA2652980A CA2652980A1 CA 2652980 A1 CA2652980 A1 CA 2652980A1 CA 002652980 A CA002652980 A CA 002652980A CA 2652980 A CA2652980 A CA 2652980A CA 2652980 A1 CA2652980 A1 CA 2652980A1
Authority
CA
Canada
Prior art keywords
formulation
oxymorphone
sustained release
ethanol
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002652980A
Other languages
English (en)
Inventor
Anand R. Baichwal
Kevin Fitzmaurice
Steve Labudzinski
Michelle Howard-Sparks
William Hein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penwest Pharmaceuticals Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2652980A1 publication Critical patent/CA2652980A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002652980A 2006-10-10 2006-10-10 Formulations d'oxymorphone robustes a liberation prolongee Abandoned CA2652980A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/039767 WO2008045046A1 (fr) 2006-10-10 2006-10-10 Formulations d'oxymorphone robustes à libération prolongée

Publications (1)

Publication Number Publication Date
CA2652980A1 true CA2652980A1 (fr) 2008-04-17

Family

ID=38169509

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002652980A Abandoned CA2652980A1 (fr) 2006-10-10 2006-10-10 Formulations d'oxymorphone robustes a liberation prolongee

Country Status (10)

Country Link
EP (1) EP2097069A1 (fr)
JP (1) JP2010505947A (fr)
KR (1) KR20090076946A (fr)
CN (1) CN101578095A (fr)
AU (1) AU2006349471A1 (fr)
BR (1) BRPI0621952A2 (fr)
CA (1) CA2652980A1 (fr)
IL (1) IL198169A0 (fr)
MX (1) MX2009003772A (fr)
WO (1) WO2008045046A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1414458B1 (fr) 2001-07-06 2007-04-11 Endo Pharmaceuticals Inc. Administration orale de 6-hydroxy-oxymorphone utilise en tant qu'analgesique
EP2097070A1 (fr) * 2006-10-10 2009-09-09 Penwest Pharmaceuticals Co. Formulations à libération prolongée et stable d'oxymorphone et leurs procédés d'utilisation
EP3473246A1 (fr) 2017-10-19 2019-04-24 Capsugel Belgium NV Formulations anti-abus à libération immédiate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1414458B1 (fr) * 2001-07-06 2007-04-11 Endo Pharmaceuticals Inc. Administration orale de 6-hydroxy-oxymorphone utilise en tant qu'analgesique
BR0210855A (pt) * 2001-07-06 2006-10-24 Penwest Pharmaceuticals Compan Método de fabricação de formulações de liberação prolongada
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
EP2097070A1 (fr) * 2006-10-10 2009-09-09 Penwest Pharmaceuticals Co. Formulations à libération prolongée et stable d'oxymorphone et leurs procédés d'utilisation

Also Published As

Publication number Publication date
KR20090076946A (ko) 2009-07-13
EP2097069A1 (fr) 2009-09-09
CN101578095A (zh) 2009-11-11
JP2010505947A (ja) 2010-02-25
BRPI0621952A2 (pt) 2011-10-18
WO2008045046A1 (fr) 2008-04-17
IL198169A0 (en) 2009-12-24
MX2009003772A (es) 2009-07-22
AU2006349471A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
CA2652981C (fr) Formulations robustes a liberation prolongee
US20080085304A1 (en) Robust sustained release formulations
CA2644992C (fr) Formulations a liberation soutenue et resistant a l'ethanol
AU2002337686B2 (en) Opioid formulations having reduced potential for abuse
EP2706986B1 (fr) Nouvelle composition pharmaceutique anti-abus pour le traitement de la dépendence de l'opioide
AU2002337686A1 (en) Opioid formulations having reduced potential for abuse
US20080085305A1 (en) Robust sustained release formulations of oxymorphone
US20160367550A1 (en) Naloxone Single Agent and Multilayer Tablets
CA2969013A1 (fr) Composition pharmaceutique offrant des proprietes de prevention de l'abus
AU2006349472A1 (en) Robust sustained release formulations of oxymorphone and methods of use thereof
CA2652980A1 (fr) Formulations d'oxymorphone robustes a liberation prolongee
US20080085303A1 (en) Robust sustained release formulations of oxymorphone and methods of use thereof
KR20090065543A (ko) 옥시모르폰의 강건한 서방형 제제 및 이의 제조 및 사용
NZ709502B2 (en) New abuse-resistant pharmaceutical composition for the treatment of opioid dependence

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150130